Tumor HEVs enhance the proliferation of TCF-1+PD-1+ lymphocytes and the production of cytotoxic PD-1+TIM-3+ lymphocytes by changing the perivascular microenvironment to promote antitumor immunity (179). The gene discussed is PDCD1; the disease is neoplasm.